CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
The CO29 trial: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Sutdy, AGITG DYNAMIC-III has closed to accrual. The study reached its overall accrual target of 1000 patients, 209 of which were randomized by Canadian sites.
The inaugural CCTG Award for Excellence in Clinical Trials Conduct will be presented this year at the Recognition Awards at the Annual Spring Meeting of Participants to an individual who exemplifies excellence in clinical trial operations and/or compliance at their institution.
Mark your calendars! Dr Lillian Siu is our guest speaker this year at the Maria Ricci Memorial Lectureship In Oncology taking place at the CCTG Spring Meeting on Saturday April 29, 5:00 pm in the Mountbatten Room at the Chelsea Hotel in Toronto. Dr Siu's lecture is titled "Precision Cancer Medicine Beyond Next Generation Sequencing Gene Panels". This session is RCPSC accredited
About Dr Lillian Siu
#CCTG2023 is fast approaching and you are running out of time and if you have not register or requested an invitation please do so now!
Practice changing data presented in endometrial cancer that demonstrates improved progression-free survival outcomes with the addition of Pembrolizumab to chemotherapy for women with advanced or recurrent endometrial cancer.
CCTG is looking for members for our Equity, Diversity, Inclusivity, Indigenization, and Accessibility (EDIIA) Working Groups as part of our EDIIA Action Plan. CCTG strives to create an equitable, diverse, inclusive, accessible, and culturally safe community for our network and for patients.
